Our Approach
The alternative pathway: its dysregulation can drive pathogenesis in rare diseases
In numerous rare diseases, the complement alternative pathway (AP) is activated by an artificial surface, the body's own proteins and cells, or bacterial and viral surfaces. In these settings, dysregulation of the AP activity induces inflammation and cellular destruction, which can further exacerbate the symptoms of chronic rare diseases. NovelMed’s strategy to selectively target the AP has led to the development of several first-in-class antibody-based drugs that have shown remarkable results in disease models and in Phase I clinical trials.
Our lead drug candidates prevent the formation of C3a/C3b, C5a/C5b, and MAC via the AP. The drugs have no effect on the Classical Pathway.
